Maurizio PetitBon
General Partner @ Kreos Capital
London, United Kingdom
Maurizio PetitBon is a post-ipo debt investor at Kreos Capital in London focused on Biotechnology and Health Care. Over the past 19 years at Kreos, Maurizio has focused on identifying, assessing and managing UK and European healthcare transactions as well as participating in the management and execution of Kreos’s overall strategy. Over the past 30 years, Maurizio has built a career as manager, advisor, entrepreneur and investor. Prior to Kreos, Maurizio wasManaging Partner of PMA Europe, London, a consulting partnership focused on assisting private equity firms and corporate clients in evaluating investment opportunities in technology companies. Prior to that, Maurizio was Principal Consultant at SRI International, in Menlo Park, CA and London where he advised a number of US, European and Japanese high tech companies on business development and M&A strategies. Maurizio held a number of managerial positions in the industry including Director International Operations at ACDC Electronics, a division of Emerson Electric, Business Development Director Europe for Emerson Electric Corp and Head of OEM sales at Digital Equipment Corp. (DEC) in Milan. Maurizio started his professional career in the Financial Planning and Control group at Rank Xerox International HQ. Maurizio holds a Doctor’s degree in mechanical engineering from the University of Rome, Italy and an MBA from INSEAD. Maurizio is fluent in English, French and Italian.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Maurizio PetitBon invests in
Stages Maurizio PetitBon invests in
Countries Maurizio PetitBon invests in
Investment Focus
Industry
- Biotechnology 6 (86%)
- Health Care 5 (71%)
- Medical Device 3 (43%)
- Manufacturing 2 (29%)
- Pharmaceutical 2 (29%)
Stage
- Post-IPO Debt 5 (71%)
- Post-IPO Equity 1 (14%)
Country
- France 2 (29%)
- Switzerland 2 (29%)
- Germany 1 (14%)
- The Netherlands 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TME Pharma
|
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin,Germany. | $580.7K / Post-IPO Debt / Aug 25, 2025 | |
Sequana Medical
|
Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $10.2M / Post-IPO Debt / Jul 20, 2022 | |
VectivBio
|
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and theirfamilies, not just provide an incremental improvement or benefit over the standard-of-care.It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland. | $75M / Post-IPO Debt / Mar 30, 2022 | |
NicOx
|
NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donatingcompound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France. | $21.9M / Post-IPO Debt / Jan 25, 2019 | |
SuperSonic Imagine
|
SuperSonic Imagine SA develops and manufactures ultrasound medical imaging systems for measuring and visualizing tissue elasticity. The company provides Aixplorer, an ultrasound system for breast lesion imaging; and ShearWave, an ultrasound technology platform for quantitative elastography. It offers its products through its offices and a networkof distributors in France, Belgium, Austria, Croatia, Poland, the Czech Republic, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Lebanon, Germany, the United Kingdom, and the United States. SuperSonic Imagine SA was founded in 2005 and is based in Aix-en-Provence, France with additional offices in Germany, the United States, and the United Kingdom. | $13.2M / Post-IPO Equity / Dec 17, 2018 | |
Kiadis Pharma
|
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma isheadquartered in Amsterdam, The Netherlands. | $21.9M / Post-IPO Debt / Aug 01, 2018 | |
|
Kiadis Pharma
|
Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma isheadquartered in Amsterdam, The Netherlands. | $16.5M / Post-IPO Debt / Aug 17, 2017 |
About Kreos Capital
Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has aproven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.
Kreos Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aris Constantinides
General Partner
|
|||
Jonne de Leeuw
Venture Partner
|
|||
Marten Vading
General Partner
|
|||
|
Maurizio PetitBon
General Partner
|
|||
Melissa Donohoe
Associate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Maurizio PetitBon invest in?
Maurizio PetitBon invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Post-IPO Debt and Post-IPO Equity stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Maurizio PetitBon last invest?
The most recent investment recorded for Maurizio PetitBon closed in Aug 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
